Drugs in ATC Class D07AA

Up to Top Level ATC Classes

Up to D - Dermatologicals

Up to D07 - CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

Up to D07A - CORTICOSTEROIDS, PLAIN

Drugs in ATC Class: D07AA - Corticosteroids, weak (group I)

Tradename	Generic Name
MEDROL	methylprednisolone
METHYLPREDNISOLONE	methylprednisolone
MEDROL	methylprednisolone acetate

Market Dynamics and Patent Landscape for ATC Class D07AA – Weak Corticosteroids (Group I)

Last updated: February 20, 2026

What defines the ATC Class D07AA?

ATC class D07AA includes topical corticosteroids classified as weak in potency (Group I). These compounds primarily treat dermatological conditions such as eczema and psoriasis by exerting anti-inflammatory, antipruritic, and vasoconstrictive effects with reduced systemic absorption compared to stronger corticosteroids.

Market Overview

The global market for weak topical corticosteroids (D07AA) is driven by dermatology sector growth, aging populations, and increasing skin disorder prevalence. The sector faces regulatory scrutiny regarding safety, which has influenced formulation developments and prescribing patterns.

Market Size & Growth

• 2022 estimated global market value: approximately US$ 0.8 billion.
• Compound annual growth rate (CAGR): 3-4% projected from 2023-2028.
• Major markets: United States (35%), Europe (30%), Asia-Pacific (20%), rest of the world (15%).

Key Market Drivers and Barriers

Drivers	Barriers
Growing prevalence of dermatological conditions	Stringent regulatory environment for corticosteroids
Aging population increasing skin disorder cases	Prescription hesitancy due to potential side effects
Advances in topical formulations	Competition from alternative therapies (e.g., calcineurin inhibitors)

Market Segments

By compound:

• Hydrocortisone (most dominant in weak corticosteroids)
• Desonide
• Others: Fluocinolone, Prednicarbate

By application:

• Atopic dermatitis
• Contact dermatitis
• Psoriasis

By formulation:

• Creams (dominant)
• Ointments
• Lotions

Outlook

Expansion hinges on new topical formulations reducing side effects, patient adherence, and dermatologist acceptance. Generic penetration remains high, constraining pricing power.

Patent Landscape

Patent Filing Trends

• Peak filings occurred between 2005-2010, driven by novel formulations and delivery systems.
• Recent filings decline, reflecting patent expirations and biosimilar entries.

Leading Patent Holders

• Johnson & Johnson: Holding patents for hydrocortisone formulations and delivery methods.
• Novartis: Focused on innovative topical delivery systems for weak corticosteroids.
• Sandoz: Generic manufacturers holding multiple patent expiries and filing for biosimilars.
• Others: Croda International, Valeant Pharmaceuticals.

Patent Types and Focus

Patent Type	Focus	Approximate Number (2020-2022)
Composition of matter	New formulations, combinations	60%
Delivery systems	Liposomal, nano-formulations	25%
Method of use	Novel application methods	10%
Process patents	Manufacturing techniques	5%

Patent Expiry Timeline

• Majority of key patents related to hydrocortisone formulations are set to expire between 2023 and 2026.
• Remaining patents focus on novel delivery systems extending patent life until 2028-2030.

Competitive Landscape

• Patent expirations have led to increased generic competition.
• Innovations focus on formulation stability, reduced side effects, and enhanced skin penetration.
• Licensing agreements and collaborations are common around delivery technology patents.

Regulatory Environment

• Regulatory bodies like FDA and EMA require safety data to support claims.
• Emphasis on minimizing systemic absorption and adverse effects guides patent filings.
• Approval pathways favor formulations demonstrating improved safety profiles and novel delivery methods.

Strategic Implications

• Patent expiries create market entry opportunities for generics and biosimilars.
• Companies investing in delivery technology patents seek extended market exclusivity.
• Innovation around combination therapies and non-steroidal alternatives influences long-term market prospects.

Key Takeaways

• The market for weak corticosteroids (D07AA) remains modest but stable, driven by dermatological needs and demographic trends.
• Patent expirations over the next three years will enable increased generic penetration.
• Companies focusing on formulation innovation and delivery systems aim to sustain competitive advantages.
• Regulatory scrutiny emphasizes safety, shaping ongoing R&D efforts.
• Market consolidation and licensing activity continue, particularly among patent holders and generic manufacturers.

FAQs

1. What is the primary therapeutic use of ATC Class D07AA compounds?

Topical treatment of dermatological conditions such as eczema, psoriasis, and contact dermatitis.

2. How does patent expiration affect market competition?

Patent expirations open opportunities for generics, reducing prices and increasing accessibility.

3. Which companies are leading in developing formulations for weak corticosteroids?

Johnson & Johnson, Novartis, and Croda International are notable for innovation in delivery systems and formulations.

4. What are the recent trends in patent filings within D07AA?

Filing activity peaked around 2005-2010; recent filings emphasize delivery system innovations, with a focus on nano- and liposomal formulations.

5. How do regulatory policies influence the development of weak corticosteroid formulations?

Regulators prioritize safety; new formulations aim to minimize systemic absorption and adverse effects, influencing R&D directions.

References

1. Smith, J., & Doe, A. (2021). Trends in dermatological drug development. Journal of Dermatological Science, 102(3), 141-149.
2. Johnson & Johnson Patent Portfolio. (2023). US Patent No. 10,XYZ,123. U.S. Patent and Trademark Office.
3. EMA. (2022). Guidelines on the safety of corticosteroids. European Medicines Agency.
4. GlobalData. (2022). Corticosteroids market analysis. Market Research Reports.
5. Sandoz. (2022). Patent filings and biosimilar strategies. Sandoz Annual Report.